Zytiga Phase III Halt Raises Stakes in Prostate Cancer
By Marie Powers
Friday, March 9, 2012
Shares of Medivation Inc. and Dendreon Corp. took opposite trajectories Thursday after Janssen Research & Development LLC unblinded its Phase III study of Zytiga (abiraterone acetate) plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (CRPC) who had not received chemotherapy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.